Page last updated: 2024-09-05

erlotinib hydrochloride and Adenocarcinoma, Clear Cell

erlotinib hydrochloride has been researched along with Adenocarcinoma, Clear Cell in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Akar, U; Bartholomeusz, C; Esteva, FJ; Kazansky, A; Kigawa, J; Kondo, K; Krishnamurthy, S; Lee, J; Liu, P; Oishi, T; Saso, H; Ueno, NT	1
Baughman, C; Edwards, DL; Greco, A; Hainsworth, JD; Sosman, JA; Spigel, DR	1

Trials

1 trial(s) available for erlotinib hydrochloride and Adenocarcinoma, Clear Cell

Article	Year
Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Nov-01, Volume: 23, Issue:31 Topics: Adenocarcinoma, Clear Cell; Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome	2005

Article

Year

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Nov-01, Volume: 23, Issue:31

Topics: Adenocarcinoma, Clear Cell; Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome

2005

Other Studies

1 other study(ies) available for erlotinib hydrochloride and Adenocarcinoma, Clear Cell

Article	Year
MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. Molecular cancer therapeutics, 2012, Volume: 11, Issue:2 Topics: Adenocarcinoma, Clear Cell; Animals; Apoptosis Regulatory Proteins; Benzimidazoles; Blotting, Western; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; G1 Phase; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Nude; Ovarian Neoplasms; Phosphoproteins; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays	2012

Article

Year

MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.

Molecular cancer therapeutics, 2012, Volume: 11, Issue:2

Topics: Adenocarcinoma, Clear Cell; Animals; Apoptosis Regulatory Proteins; Benzimidazoles; Blotting, Western; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; G1 Phase; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Nude; Ovarian Neoplasms; Phosphoproteins; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays

2012